Assessing Risk of Fatality in Chronic Heart Failure Patients, using Nocturnal Periodicity Biomarker of Cardiopulmonary Coupling

Reference:
Hilmisson H, Magnusdottir S. Assessing risk of fatality in chronic heart failure patients, using nocturnal periodicity biomarker of cardiopulmonary coupling. Sleep Medicine 2019. DOI: 10.1016/j.sleep2019.11.423

Objectives:
Chronic Heart Failure (CHF) is a leading cause for hospitalization globally with high 30-day readmission rates. Cheyne-Stokes respiration (periodic breathing) is prevalent in CHF-patients, which increases with deteriorating cardiac function and is associated with poor outcomes. Cardiopulmonary Coupling (CPC) is ECG-based Software as a Medical Device (SaMD), providing information on cardiorespiratory health during sleep that displays CPC-biomarker eLFCNB, which is associate with periodic breathing, central apnea and high loop gain obstructive sleep apnea. As such, we investigated the viability of using eLFCNB as a risk factor of fatality in CHF patients.

Conclusions:

Results indicate that subjects who experienced CHF-event during the study had higher levels of eLFCNB (6.7% vs. 3.8%; p<0.001). In subjects with previous history of CHF average levels of eLFCNB were significantly higher in those experiencing a CHF-event during the study period when compared to those that did not experience a CHF-event (10.5% vs. 6.2%; p,0.001). Given previous history of CHF, higher levels of eLFCNB were associated with increased risk of fatality following a CHF-event.

Practical Significance:

The CPC-biomarker of eLFCNB may offer a predicative metric describing disease progression for CHF-patients.

View Publication

Assessing Risk of Fatality in Chronic Heart Failure Patients, using Nocturnal Periodicity Biomarker of Cardiopulmonary Coupling